Antibiotics Currently in Global Clinical Development (update)
As of December 2020, approximately 43 new antibiotics with the potential to treat serious bacterial infections were in clinical development.
The interactive resource – based on publicly available information and informed by external experts and company communication – focuses exclusively on small molecule products that act systemically (drugs that work throughout the body), contain at least one component not previously approved, and have the potential to treat serious or life-threatening infections. To view subsets of antibiotics in development, use filter options.
OUR UNDERWRITERS
Unrestricted financial support by:
 |
Antimicrobial Resistance Fighter Coalition |
 |
Evotec |
 |
JSS University |
Technology Database
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.
